Agilis forms joint venture to advance gene therapy vectors – FierceBiotech
FierceBiotech |
Agilis forms joint venture to advance gene therapy vectors
FierceBiotech Agilis Biotherapeutics has formed a joint venture with Japan’s Gene Therapy Research Institution (GTRI). The alliance gives Agilis a base in Japan and a partnership with a fellow CNS specialist to support its development of adeno-associated virus (AAV) … Agilis Biotherapeutics and Gene Therapy Research Institution Enter into Strategic PartnershipBusiness Wire (press release) |
|
Cancer Research Institute and Israel Cancer Research Fund Announce Launch of the Immunotherapy Promise Initiative
Newswise (press release) Newswise — NEW YORK, August 2, 2017—The Cancer Research Institute (CRI) and Israel Cancer Research Fund (ICRF) today announced the establishment of The Immunotherapy Promise™ fund, a groundbreaking, collaborative campaign bringing … |
|
Cancer Research Institute and Israel Cancer Research Fund Announce Launch of the Immunotherapy Promise Initiative
Newswise (press release) Newswise — NEW YORK, August 2, 2017—The Cancer Research Institute (CRI) and Israel Cancer Research Fund (ICRF) today announced the establishment of The Immunotherapy Promise™ fund, a groundbreaking, collaborative campaign bringing … |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
PR Newswire (press release) … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
PR Newswire (press release) … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
PR Newswire (press release) … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |